Scroll to top

Meet the Board
and management

CLINUVEL’s Board of Directors oversee the direction, risk
 management and financial performance of the CLINUVEL Group.

Our management team have more than 60 years of tenure at
 CLINUVEL and are responsible for driving company performance.

Our People.

Board of Directors

Mr Willem Blijdorp

Non-executive Chairman, voting member of the Audit & Risk Committee, Chair of the Remunerations Committee, Chair of the Nomination Committee

Mr Blijdorp joined the CLINUVEL board in 2015. He is the founding member, majority shareholder and a current supervisory Director of B&S International NV, a privately owned Dutch group focused on the wholesale and international trading of luxury and fast moving consumer goods and pharmaceutical products. He managed B&S International for 27 years as CEO and remains actively involved in the company’s expansion strategy, helping it to become one of the largest trading houses globally with a compounded annual growth rate of 10% for the past decade. Being recognised for his expertise in merger and acquisitions and leadership, in 2014 Mr Blijdorp was awarded the Ernst & Young Entrepreneur of the Year in the Netherlands.

Other affiliations: Director, B&S International NV

Dr Philippe Wolgen

Managing Director and Chief Executive Officer

Dr Wolgen joined the CLINUVEL board in 2005 and brings his finance experience and professional contacts in European capital markets to the Company. As a former equity analyst, his in-depth analysis and expertise of the life science sector has been an asset to CLINUVEL. Previously, he held positions in private pharmaceutical companies in Europe, as MD of two medical centres in the UK and Israel, and consulted medical device companies. He has been instrumental in raising A$95 million since 2006 for the funding of the current development program of SCENESSE® (afamelanotide 16mg).

Dr Wolgen holds an MBA from Columbia University NY and the London Business School and an MD from the University of Utrecht, the Netherlands.

Mrs Brenda Shanahan

Non-executive Director, Chair of the Audit and Risk Committee, voting member of the Nomination Committee

Mrs Shanahan joined CLINUVEL in 2007 and was Non-Executive Chair of the Board from late 2007 until July 2010. Her depth of experience across global markets and medical research provides significant value to the current Board and Company.

Mrs Shanahan is an established member of the Australian finance community with more than two decades working and investing in medical R&D and commercialisation. Previously, Mrs Shanahan was a member of the Australian Stock Exchange, an executive director of a stockbroking firm, a fund management company and an actuarial company, and chair of the St Vincent’s Medical Research Institute. She was also Chair of Challenger Listed Investments Ltd, the reporting entity for four ASX listed firms (CKT, CIF, CDI and CWT) and a non-executive director of Challenger Limited (ASX: CGF).

Other affiliations: Chair of St Vincent’s Medical Research Institute in Melbourne; non-Executive Director of DMP Asset Management; non-Executive Director of Challenger Limited (ASX:CGF); non-Executive Director of Bell Financial Group (ASX: BFG); non-Executive Director of Phoslock Ltd (ASX: PHK)and Director of the Kimberley Foundation of Australia.

Dr Karen Agersborg

Non-executive Director, voting member of the Remuneration Committee, voting member of the Nomination Committee

Dr Agersborg joined the CLINUVEL board in 2018 and is a Board-Certified Endocrinologist in Pennsylvania, USA. She currently servies as Clinical Endocrinologist at Easton Hospital, specialising in Endocrinology, Diabetes & Metabolism. Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital.

Prior to obtaining a Doctorate of Oesteopathic Medicine at the Philadelphia College of Osteopathic Medicine where she volunteers as Clinical Instructor and prior to completing her Fellowship at Temple University Hospital, Dr Agersborg had an extensive career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories).

Other affiliations: Board-Certified Endocrinologist in Pennsylvania, USA; Clinical Endocrinologist at Reading Hospital; Member of the American Osteopathic Association; Fellow of the American Association of Clinical Endocrinologists; and Fellow of the American College of Osteopathic Internists.

Mrs Susan Smith

Non-executive Director, voting member of the Remuneration Committee, voting member of the Nomination Committee

Mrs Susan Smith is an experienced senior healthcare executive based in London and joined the CLINUVEL board in 2019. Mrs Smith is the Chief Executive Officer (CEO) of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages an established consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors.

Prior to her current roles Mrs Smith led a distinguished career, serving for 14 years as CEO of The Princess Grace Hospital, London, and 11 years as the CEO of The Portland Hospital for Women and Children, London. Mrs Smith’s specific expertise is in implementation of operational strategies within complex and acute care environments, and in the interaction with healthcare authorities and UK regulators.

Other affiliations: Non-Executive Board Chair of The Evewell (Harley Street) Limited, Non-Executive Director of Elite Medicine Ltd, and a Trustee of the HCA International Foundation.

Professor Jeffrey V. Rosenfeld AC, OBE

Non-executive Director, voting member of the Audit & Risk Committee, voting member of the Nomination Committee

Dr Rosenfeld joined the CLINUVEL board in 2019. He is a neurosurgeon with extensive experience in senior healthcare and research executive roles and a distinguished career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands.

Other affiliations: Professor of Surgery, Monash University; Senior Neurosurgeon, The Alfred Hospital; Adjunct Professor in Surgery, F. Edward Hébert School of Medicine; Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA; Major General (Ret’d), Australian Army

Management

Dr Dennis Wright

Chief Scientific Officer

Dr Wright has a broad range of experience in the pharmaceutical industry spanning 25 years. He spent over 17 years at CSL working predominantly in regulatory affairs with nearly a decade as Regulatory Affairs Manager. Most recently he was Global Pharmacovigilance Manager and Regulatory Affairs Manager for the Australian and New Zealand operations of Mayne Pharma, part of Halcygen (ASX:HGN).

He has a Pharmacy degree and post-graduate qualifications from University of Sydney and Health Economics qualifications from Monash University, Melbourne. Dr Wright is responsible for leading the clinical and regulatory development team and progressing afamelanotide through to regulatory approval in global markets. Qualifications: BPharm, MSc, PhD

Mr Darren Keamy

Chief Financial Officer, Company Secretary

Mr Keamy is a qualified CPA who joined CLINUVEL in November 2005 after working in key management accounting and commercial roles in Amcor Limited over a period of nine years.

He also spent two years working in the UK, gaining experience in financial regulation and control within the banking and retail pharmaceutical industries. Qualifications: BComm, CPA

Mr Lachlan Hay

Director of Global Operations

Mr Hay is General Manager of CLINUVEL’s European office, focused on the roll out of CLINUVEL’s drug SCENESSE® (afamelanotide 16mg) in Europe for the treatment of adult patients with the ultra-orphan disorder erythropoietic protoporphyria (EPP). He has over a decade of diverse experience with the CLINUVEL Group, having held communications and operations positions in Australia, Switzerland and Europe.

Mr Hay has previously held marketing communications roles in the not-for-profit sector in Australia. He holds a BA (Media & Communications) from the University of Melbourne, Australia, and a MA (International Relations) from the Freie Universität Berlin, Germany. Qualifications: BA, MA

Corporate Governance

The CLINUVEL Board is committed to good corporate governance. CLINUVEL’s corporate governance policies are available for review and download via the links on the right.

CLINUVEL’s 2017 methodological note to disclosures made under the ABPI Code of Conduct can be downloaded here

Contact

Questions?
Get in touch.

We use cookies to give you the best experience.